Treatment of Chikungunya Virus Disease in the Chronic Phase
A subset of patients with Chikungunya virus disease progress beyond the acute and sub-acute stages into a
chronic phase, where musculoskeletal symptoms — particularly joint pain and inflammation —
persist and can significantly impair daily function and quality of life.
Clinical Situation
Clinical management of Chikungunya is based on the phase of the disease. In the chronic phase,
the treatment objectives are to limit potential joint damage, decrease the functional and
psychological impact, and improve the patient's quality of life.
Severity of symptoms is assessed using a visual analogue scale (VAS), stratifying patients
into moderate (VAS 4–6) or severe (VAS 7–10) presentations — each tier guiding the intensity
of the therapeutic approach.
Treatment Approach (Overview)
For patients in the chronic phase with moderate to severe symptoms, a short course of
corticosteroid therapy may be considered — particularly when this class of treatment
was not used during the preceding sub-acute phase.
The full protocol specifies the agent, dosing schedule, and tapering algorithm — access the complete regimen below.
References
- The clinical management of Chikungunya is based on the phase of the disease.
- The treatment objectives in this phase of illness are to limit the potential joint damage, decrease the functional and psychological impact and improve the quality of life.
- A short course of corticosteroids may be used in this phase if not used previously. The dose, duration, and weaning algorithm may be the same as suggested previously in the sub-acute phase.
- Short course of corticosteroids may be given if not used previously in the sub-acute phase for moderate (VAS score 4–6) to severe symptoms (VAS score 7–10).
View source ↗